Table 2.

Published Measures of Suicidality

Trial	Measure Used	Outcome Reported in Publication
Berman et al., 2000	HAM-D suicidality item	While undergoing active treatment, significant decreases were observed for suicidality (P < .02). Control treatment was not associated with significant improvement in any of the HAM-D items.
Zarate et al., 2006	HAM-D suicidality item	Significant main effect for drug
Zarate et al., 2012	Changes in suicide item scores on the MADRS, HAM-D, and BDI	Within 40min, suicidal ideation significantly improved in subjects receiving ketamine compared with placebo (Cohen’s d 0.98, 95% CI 0.64 –1.33); this improvement remained significant through day 3. Reductions in suicide item scores for each of the MADRS, HAM-D, and BDI using linear mixed models (each P <.001)
Murrough et al., 2013	Composite index of explicit suicidal ideation (Beck Scale for Suicidal Ideation, MADRS suicide item, Quick Inventory of Depressive Symptoms suicide item)	Fifty-three percent of ketamine-treated patients scored 0 on all 3 explicit suicide measures at 24h compared with 24% of the midazolam group (χ = 4.6; P = .03)

Abbreviations: BDI, Beck Depression Inventory; HAM-D, Hamilton Depression Rating Scale; MADRS, Montgomery Åsberg Rating Scale.